MP72-15 LONG-TERM CHANGES IN RENAL FUNCTION AFTER LIVING DONOR NEPHRECTOMY: PREDICTING FACTORS OF CHRONIC KIDNEY DISEASE

Abstract

were placed. Total narcotic use was converted to IV morphine equivalents. Maximum visual analog pain scores (VAS) were noted. Cost of adjunct perioperative analgesia was compared. Statistical analysis consisted of student’s T-test, Chi-square, and ANOVA, with significance < 0.05. RESULTS: 195 patients underwent LESS-DN between October 2011 and September 2013. Pain was managed with LB (n1⁄450), SFCLA (n1⁄468), or PCA (n1⁄477). Patients managed with PCA used more narcotics than those on LB (63.3 mg vs. 29.4 mg, p<0.01) or SFCLA (vs. 32.9 mg, p<0.01). Narcotic use was similar between LB and SFCLA (p1⁄40.43). PCA patients had a lower max VAS than patients on LB (5.2 vs. 6.3, p1⁄40.02) or SFCLA (vs. 6.2, p1⁄40.04). Operating time was longer for SFCLA compared to LB (219.8 min vs. 199.3 min, p<0.01) and PCA (vs. 202 min, p<0.01). There was no difference in length of stay (p1⁄40.89), age (p1⁄40.45), gender (p1⁄40.85), BMI (p1⁄40.20), operative side (p1⁄40.98), or preand post-operative GFR (p1⁄40.95, p1⁄40.45). The cost of LB is approximately $285; the cost of SFCLA is approximately $460 for the device plus $400 for the ropivacaine. CONCLUSIONS: LB is as effective as SFCLA in providing perioperative analgesia while decreasing OR time, likely due to its comparative ease of administration. Although patients with PCA showed slightly lower maximum VAS scores than those with LB or SFCLA, it is not likely clinically significant. Cost of LB is significantly lower than SFCLA.